Bronchopulmonary Dysplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bronchopulmonary dysplasia markets reached a value of US$ 269.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The bronchopulmonary dysplasia market has been comprehensively analyzed in IMARC's new report titled "Bronchopulmonary Dysplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchopulmonary dysplasia (BPD) refers to a chronic lung disease that primarily affects premature infants who require oxygen therapy and mechanical ventilation for acute respiratory distress syndrome or other neonatal respiratory problems. It is characterized by the abnormal development of lung tissue, inflammation, and scarring, which can lead to chronic respiratory symptoms, including wheezing, coughing, difficulty in breathing, etc. The severity of BPD can vary widely, with some infants experiencing mild indications that improve over time, while others require ongoing medical treatment and may develop long-term complications such as pulmonary hypertension, developmental delay, and growth impairment. The diagnosis of the ailment is typically made based on the infant's medical history, physical exam, and diagnostic tests. Several laboratory investigations are performed, including a chest X-ray, blood gas analysis, pulmonary function tests, and echocardiography to evaluate lung function, oxygen levels, and blood flow. In many cases, a lung biopsy may be necessary to confirm the diagnosis and rule out other respiratory conditions.
The increasing cases of lung injury and inflammation caused by several risk factors, including mechanical ventilation, oxygen toxicity, infections like pneumonia and sepsis, etc., are primarily driving the bronchopulmonary dysplasia market. Furthermore, the inflating application of bronchodilators, such as beta-agonists and anticholinergics, for relieving breathing difficulties in infants with BPD is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of diuretics, since they reduce fluid buildup in the lungs, which can help improve breathing and lower the risk of complications like pneumonia, is creating a positive outlook for the market. Moreover, the growing awareness regarding the long-term effects of BPD on infants has led to an increased interest in the development of new therapies and better management strategies. This, in turn, is also propelling the market growth. Additionally, the escalating demand for non-invasive ventilation, such as nasal continuous positive airway pressure (nCPAP), on account of its numerous associated benefits, including improved oxygenation and reduced need for invasive mechanical ventilation, is expected to drive the bronchopulmonary dysplasia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchopulmonary dysplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchopulmonary dysplasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchopulmonary dysplasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchopulmonary dysplasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchopulmonary dysplasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchopulmonary dysplasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchopulmonary dysplasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchopulmonary dysplasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchopulmonary dysplasia across the seven major markets?
What is the size of the bronchopulmonary dysplasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchopulmonary dysplasia?
What will be the growth rate of patients across the seven major markets?
Genital warts: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchopulmonary dysplasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchopulmonary dysplasia market?
What are the key regulatory events related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by status related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by phase related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by route of administration related to the bronchopulmonary dysplasia market?
The bronchopulmonary dysplasia market has been comprehensively analyzed in IMARC's new report titled "Bronchopulmonary Dysplasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchopulmonary dysplasia (BPD) refers to a chronic lung disease that primarily affects premature infants who require oxygen therapy and mechanical ventilation for acute respiratory distress syndrome or other neonatal respiratory problems. It is characterized by the abnormal development of lung tissue, inflammation, and scarring, which can lead to chronic respiratory symptoms, including wheezing, coughing, difficulty in breathing, etc. The severity of BPD can vary widely, with some infants experiencing mild indications that improve over time, while others require ongoing medical treatment and may develop long-term complications such as pulmonary hypertension, developmental delay, and growth impairment. The diagnosis of the ailment is typically made based on the infant's medical history, physical exam, and diagnostic tests. Several laboratory investigations are performed, including a chest X-ray, blood gas analysis, pulmonary function tests, and echocardiography to evaluate lung function, oxygen levels, and blood flow. In many cases, a lung biopsy may be necessary to confirm the diagnosis and rule out other respiratory conditions.
The increasing cases of lung injury and inflammation caused by several risk factors, including mechanical ventilation, oxygen toxicity, infections like pneumonia and sepsis, etc., are primarily driving the bronchopulmonary dysplasia market. Furthermore, the inflating application of bronchodilators, such as beta-agonists and anticholinergics, for relieving breathing difficulties in infants with BPD is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of diuretics, since they reduce fluid buildup in the lungs, which can help improve breathing and lower the risk of complications like pneumonia, is creating a positive outlook for the market. Moreover, the growing awareness regarding the long-term effects of BPD on infants has led to an increased interest in the development of new therapies and better management strategies. This, in turn, is also propelling the market growth. Additionally, the escalating demand for non-invasive ventilation, such as nasal continuous positive airway pressure (nCPAP), on account of its numerous associated benefits, including improved oxygenation and reduced need for invasive mechanical ventilation, is expected to drive the bronchopulmonary dysplasia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchopulmonary dysplasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchopulmonary dysplasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchopulmonary dysplasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchopulmonary dysplasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchopulmonary dysplasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchopulmonary dysplasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchopulmonary dysplasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchopulmonary dysplasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchopulmonary dysplasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchopulmonary dysplasia across the seven major markets?
What is the size of the bronchopulmonary dysplasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchopulmonary dysplasia?
What will be the growth rate of patients across the seven major markets?
Genital warts: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchopulmonary dysplasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchopulmonary dysplasia market?
What are the key regulatory events related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by status related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by phase related to the bronchopulmonary dysplasia market?
What is the structure of clinical trial landscape by route of administration related to the bronchopulmonary dysplasia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHOPULMONARY DYSPLASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHOPULMONARY DYSPLASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHOPULMONARY DYSPLASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHOPULMONARY DYSPLASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHOPULMONARY DYSPLASIA - UNMET NEEDS
10 BRONCHOPULMONARY DYSPLASIA - KEY ENDPOINTS OF TREATMENT
11 BRONCHOPULMONARY DYSPLASIA - MARKETED PRODUCTS
11.1 List of Bronchopulmonary Dysplasia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHOPULMONARY DYSPLASIA - PIPELINE DRUGS
12.1 List of Bronchopulmonary Dysplasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Pneumostem - Medipost
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 UMC 119 01 - Meridigen Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AT 100 - Airway Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OHB-607- Oak Hill Bio/ Takeda
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHOPULMONARY DYSPLASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHOPULMONARY DYSPLASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHOPULMONARY DYSPLASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchopulmonary Dysplasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchopulmonary Dysplasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchopulmonary Dysplasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchopulmonary Dysplasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchopulmonary Dysplasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchopulmonary Dysplasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchopulmonary Dysplasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchopulmonary Dysplasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
16 BRONCHOPULMONARY DYSPLASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHOPULMONARY DYSPLASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHOPULMONARY DYSPLASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHOPULMONARY DYSPLASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHOPULMONARY DYSPLASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHOPULMONARY DYSPLASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHOPULMONARY DYSPLASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHOPULMONARY DYSPLASIA - UNMET NEEDS
10 BRONCHOPULMONARY DYSPLASIA - KEY ENDPOINTS OF TREATMENT
11 BRONCHOPULMONARY DYSPLASIA - MARKETED PRODUCTS
11.1 List of Bronchopulmonary Dysplasia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHOPULMONARY DYSPLASIA - PIPELINE DRUGS
12.1 List of Bronchopulmonary Dysplasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Pneumostem - Medipost
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 UMC 119 01 - Meridigen Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AT 100 - Airway Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OHB-607- Oak Hill Bio/ Takeda
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHOPULMONARY DYSPLASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHOPULMONARY DYSPLASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHOPULMONARY DYSPLASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchopulmonary Dysplasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchopulmonary Dysplasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchopulmonary Dysplasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchopulmonary Dysplasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchopulmonary Dysplasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchopulmonary Dysplasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchopulmonary Dysplasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchopulmonary Dysplasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchopulmonary Dysplasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchopulmonary Dysplasia - Access and Reimbursement Overview
16 BRONCHOPULMONARY DYSPLASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHOPULMONARY DYSPLASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHOPULMONARY DYSPLASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
